Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.

Because of advances in linker conjugation chemistry and our understanding of the ADC mechanism of action in vivo, an increasing breadth of anticancer agents are now being incorporated in newer ADC ...

Explore the World ADC Conference highlights on antibody-drug conjugates and their impact on cancer therapy and clinical ...

BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data ...

Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

What are the biggest hurdles preventing the wider adoption/utilization of ADCs? Stability and toxicity are two of the major challenges. First, linker stability issues result in the immediate release ...